Creative Biolabs) New Ways of Evaluating the Tumor Immune Microenvironment      
작성자
abbabio
작성일자
2020-11-11
조회수
245
New Ways of Evaluating the Tumor Immune Microenvironment: From Bench to Bedside
November 18th, 2020 11 AM EST / November 18th, 2020 5 PM CET
T-cell redirecting therapies with gene-engineered CAR T-cells and T-cell engaging bispecific antibodies (bsAbs) are showing promising results in clinical trials. To guide precision immunotherapy, other factors should also be taken into consideration, including greater availability of immune targets and compounds with different modes of action during the development of new biomarkers, and determinants of response and resistance to a specific regimen.
In this technical session, Creative Biolabs has invited Dr. Bruno Paiva to give us a clearer understanding of novel immunotherapies and the combined methods to be applied in the research of tumorigenesis and drug development.
Key webinar highlights:
Recognizing the "friend or foe" relationship between (blood) cancer and immunity
Leveraging on the immunotherapies for malignant and nonmalignant (hematological) tumors
Need for next-generation immune monitoring
Webinar Speaker
Bruno Paiva, PharmD, Ph.D.
Departments of Haematology and Immunology at the Clinica Universidad de Navarra and CIMA
Director of the Flow Cytometry Core of the University of Navarra
Creative Biolabs was founded in 2004 with an aim to conquer cancer. Over the past 10 years, Creative Biolabs has grown into a world recognized leader in antibody discovery, engineering, production, and analysis services. Our bispecific antibody (bsAb) team has a collective of experienced scientists committed to providing high-quality service to worldwide customers.
